Newsflash #516

Apr 7, 2010
1,412 views

FDA Won’t Approve Statin-Fenofibrate Combo: The FDA said it won’t approve a new combo capsule for dyslipidemia until it learns more about the safety and efficacy of the compound, a decision that may be linked to the FDA’s review of the ACCORD trial findings.

AgaMatrix and sanofi-aventis sign a long-term agreement for the development and supply of blood glucose monitoring solutions, and innovative solutions in diabetes management. What makes this unique is that this is the first time an insulin company has teamed up with a diabetes monitor company to develop programs to manage diabetes.